PRSS21 Antibody

What is PRSS21/Testisin and what are its primary biological functions?

PRSS21, also known as Testisin, is a membrane-anchored serine protease that belongs to a distinct family of genes located on human chromosome 16p13.3 and mouse chromosome 17. It is post-translationally modified by the addition of a glycosylphosphatidylinositol (GPI) membrane anchor at its carboxy terminus, which tethers it to the cell surface . This protein demonstrates tissue-specific expression, with abundant presence in spermatozoa and lower expression in microvascular endothelial cells .

Functionally, PRSS21 serves two primary roles that have been well-characterized. First, it directs epididymal sperm cell maturation and sperm-fertilizing ability. Research has demonstrated that PRSS21-deficient spermatozoa exhibit decreased motility, angulated and curled tails, fragile necks, and dramatically increased susceptibility to decapitation. These defects reflect aberrant maturation during passage through the epididymis . Second, PRSS21 acts as a novel regulator of physiological hormone-induced angiogenesis and microvascular endothelial permeability. Studies show that PRSS21 regulates VE-cadherin adhesions during angiogenesis, making it a potential target for regulating neovascular integrity .

How is PRSS21 expressed during spermatogenesis and what detection methods work best?

PRSS21 expression follows a specific pattern during spermatogenesis. Immunostaining studies have revealed that PRSS21 is predominantly expressed on human spermatids throughout spermatogenesis, with similar expression patterns observed during murine spermatogenesis . The protein has been detected in the plasma membranes of spermatocytes, further confirming its role in sperm cell development .

For detection during spermatogenesis, immunohistochemistry (IHC) has proven highly effective. Studies have successfully used anti-PRSS21 monoclonal antibodies at concentrations of approximately 8 μg/ml with incubation at room temperature for 1 hour. This approach allows for visualization of PRSS21 expression in specific cell types within testicular tissue . For optimal results, perfusion-fixed frozen sections of testis tissue have been stained using Goat Anti-Mouse Testisin/Prss21 Antigen Affinity-purified Polyclonal Antibody at 1.7 μg/mL with overnight incubation at 4°C . The use of appropriate secondary antibodies, such as Anti-Goat HRP-DAB for chromogenic detection, provides clear visualization of PRSS21 localization.

What are the optimal protocols for Western blot detection of PRSS21?

Western blot detection of PRSS21 requires careful optimization to ensure specific detection of this approximately 40 kDa protein. Based on documented protocols, researchers should begin by disrupting tissues in lysis buffer containing 1% Nonidet P-40 . After determining protein concentrations using the Bio-Rad assay, samples should be separated on 4%-12% NuPAGE Bis-Tris gels and transferred to polyvinylidene fluoride (PVDF) membranes .

For probing, PVDF membranes have been successfully probed with 0.5 μg/mL of Goat Anti-Mouse Testisin/Prss21 Antigen Affinity-purified Polyclonal Antibody, followed by HRP-conjugated Anti-Goat IgG Secondary Antibody . This concentration has proven effective for detecting specific bands at approximately 40 kDa. Importantly, experiments should be conducted under reducing conditions using appropriate immunoblot buffer systems (e.g., Immunoblot Buffer Group 1) . As a loading control, blots can be stripped and reprobed with an anti-β-actin antibody to ensure equal loading across samples .

For researchers working with both mouse and rat samples, it's worth noting that antibodies like the Goat Anti-Mouse Testisin/Prss21 Antibody (Catalog # AF6820) have demonstrated cross-reactivity with rat Testisin/Prss21, making them valuable tools for comparative studies .

What immunohistochemistry protocols yield optimal results for PRSS21 detection in tissue sections?

For immunohistochemical detection of PRSS21 in tissue sections, researchers should consider the following optimized protocol based on successful experimental approaches. For frozen tissue sections, perfusion fixation has proven effective prior to sectioning . The sections should be treated with 0.3% H₂O₂ for 30 minutes to exhaust endogenous peroxidase activity, followed by thorough washing .

Pre-incubation with 10% horse serum helps reduce background staining. For primary antibody incubation, anti-PRSS21 monoclonal antibody at 8 μg/ml has been successfully applied for 1 hour at room temperature . Alternatively, for mouse testis samples, Goat Anti-Mouse Testisin/Prss21 Antigen Affinity-purified Polyclonal Antibody at 1.7 μg/mL with overnight incubation at 4°C has yielded specific staining .

After washing in PBS, application of appropriate biotinylated secondary antibodies (e.g., anti-mouse IgG) for 30 minutes at room temperature, followed by incubation with Vectastain ABC reagent for signal amplification, has produced clear results . Development using 0.05% 3,3′-diaminobenzidine in Tris-HCl, pH 7.4 buffer with H₂O₂ as substrate, followed by light counterstaining with Mayer hematoxylin provides excellent contrast for visualization of PRSS21 localization . Negative controls should always be included by substituting PBS for the primary antibody.

How should researchers validate the specificity of PRSS21 antibodies?

Validating antibody specificity is critical for ensuring reliable research outcomes. For PRSS21 antibodies, a multi-faceted approach is recommended. First, researchers should perform Western blot analysis using both wild-type and PRSS21-deficient (Prss21-/-) tissue samples to confirm that the antibody detects a band of the expected size (approximately 40 kDa) only in wild-type samples .

Immunohistochemical validation should include comparison of staining patterns between wild-type and knockout tissues. Specific staining should be observed in the expected cellular locations, such as the plasma membranes of spermatocytes in testis tissue or in vascular endothelial cells in ovarian tissue . Additionally, researchers should include appropriate negative controls by omitting the primary antibody or using isotype controls to assess non-specific binding .

For antibodies claiming cross-reactivity between species (e.g., those detecting both human and murine PRSS21), validation should include testing on tissues from each species . If possible, competitive binding assays using recombinant PRSS21 protein can provide further evidence of specificity. Finally, correlation of protein detection with known mRNA expression patterns in different tissues can offer additional confidence in antibody specificity.

How can PRSS21 antibodies be utilized to investigate its role in vascular permeability?

Recent research has uncovered PRSS21's novel role in regulating vascular permeability and angiogenesis, providing exciting opportunities for advanced investigation using PRSS21 antibodies. When designing experiments to study this function, researchers should consider a multi-technique approach. Immunofluorescence staining using anti-PRSS21 antibodies in conjunction with endothelial cell markers can reveal the localization of PRSS21 in the microvasculature .

For functional studies, researchers can use PRSS21 antibodies to monitor protein expression changes in endothelial cells under different conditions. This approach has revealed that testisin deficiency leads to decreased expression of the adherens junction protein VE-cadherin and increased levels of phospho(Tyr658)-VE-cadherin, without affecting tight junction proteins like occludin, claudin-5, or ZO-1 . When conducting such experiments, it's essential to include appropriate controls and to verify antibody specificity in endothelial cell models.

In vivo studies comparing wild-type and Prss21-/- mice have demonstrated increased vascular leakiness in testisin-deficient animals, as evidenced by greater accumulation of extravasated Evans blue dye in ovaries . Researchers interested in this phenotype can use PRSS21 antibodies for immunohistochemical analysis of vascular structures, potentially revealing mechanisms underlying the increased permeability. The ability to correlate PRSS21 expression with vascular integrity markers provides valuable insights into its regulatory role in angiogenesis and microvascular function.

What approaches can differentiate between membrane-bound and cleaved forms of PRSS21?

Distinguishing between membrane-bound and potentially cleaved forms of PRSS21 requires sophisticated experimental approaches due to its GPI-anchored nature. Researchers should consider combining biochemical fractionation with immunoblotting to separate membrane-associated and soluble protein fractions. Since PRSS21 is tethered to the cell surface via a glycosylphosphatidylinositol (GPI) anchor , treatment with phosphatidylinositol-specific phospholipase C (PI-PLC) can release the protein from membranes, allowing researchers to distinguish anchored from free forms.

For Western blot analysis, careful sample preparation is crucial. Membrane fractions should be prepared using detergent-based lysis buffers containing 1% Nonidet P-40 , while potential soluble forms would be detected in the aqueous phase or culture supernatants. When analyzing results, researchers should be aware that membrane-bound PRSS21 might display slightly different apparent molecular weights compared to cleaved forms due to the presence or absence of the GPI anchor.

Immunofluorescence microscopy with non-permeabilized versus permeabilized cells can also help determine the localization and membrane association of PRSS21. Surface-accessible, membrane-bound PRSS21 would be detected without permeabilization, while total cellular PRSS21 would be visible after permeabilization. This approach, combined with co-localization studies using membrane markers, can provide valuable insights into the distribution and processing of PRSS21 under different experimental conditions.

How should researchers address inconsistent results between different PRSS21 antibody clones?

Inconsistencies between different PRSS21 antibody clones represent a common challenge that requires systematic troubleshooting. First, researchers should carefully examine the epitopes recognized by each antibody. Different antibodies target distinct regions of PRSS21, such as AA 121-221 , AA 20-54, or N-terminal regions , which may exhibit different accessibility depending on protein conformation, post-translational modifications, or protein-protein interactions.

When faced with discrepancies, researchers should run side-by-side comparisons using identical samples and standardized protocols. Western blotting with recombinant PRSS21 protein as a positive control can help assess whether each antibody recognizes the target protein. Additionally, testing the antibodies on tissues from PRSS21 knockout mice (Prss21-/-) provides a definitive negative control to evaluate non-specific binding .

Documentation of experimental conditions is crucial for resolving inconsistencies. Factors such as fixation methods for immunohistochemistry, lysis conditions for Western blotting, and incubation times/temperatures can significantly impact antibody performance. For instance, some antibodies perform optimally at 1.7 μg/mL overnight at 4°C for IHC applications , while others may require different conditions. Finally, consulting published validation data for each antibody and reaching out to manufacturers for technical support can provide valuable insights into resolving discrepancies.

What controls are essential when investigating PRSS21 function in knockout models?

When investigating functional phenotypes, such as spermatozoa defects or vascular permeability, quantitative measurements with appropriate statistical analysis are crucial. For instance, studies examining vascular leakiness have utilized Evans blue dye extravasation as a quantifiable metric . Similarly, sperm function studies should include objective measurements of motility, morphology, and fertilizing capacity . In all cases, blinded analysis prevents observer bias, especially for phenotypic assessments with subjective components.

How can PRSS21 antibodies contribute to understanding its role in reproductive biology disorders?

PRSS21 antibodies offer powerful tools for investigating reproductive biology disorders, particularly given the protein's essential role in sperm maturation. Research has established that PRSS21-deficient spermatozoa exhibit numerous functional abnormalities, including increased tendency toward decapitation, heterogeneity in form, angulated flagella, decreased motility, and abnormal volume regulation . These defects contribute to reduced fertilizing capacity, suggesting that PRSS21 dysfunction may underlie certain forms of male infertility.

Researchers investigating idiopathic male infertility, which affects approximately 25%-40% of infertile men, can utilize PRSS21 antibodies to examine protein expression and localization in patient samples . Immunohistochemical analysis of testicular biopsies using antibodies that specifically recognize human PRSS21 can reveal whether expression patterns differ between fertile and infertile individuals. Similarly, immunostaining of sperm samples could identify abnormalities in PRSS21 distribution, potentially correlating with functional defects.

For mechanistic studies, co-immunoprecipitation experiments using validated PRSS21 antibodies can identify interaction partners that might be disrupted in pathological conditions. Additionally, combining PRSS21 immunodetection with markers of sperm maturation could provide insights into the specific stages at which defects occur. Such approaches may ultimately lead to the development of diagnostic tools for certain forms of male infertility or even therapeutic strategies targeting PRSS21-dependent pathways.

What are the potential applications of PRSS21 antibodies in cancer research?

While the provided search results focus primarily on PRSS21's roles in reproductive and vascular biology, emerging research suggests potential applications for PRSS21 antibodies in cancer research. As a membrane-anchored serine protease, PRSS21 may participate in proteolytic cascades relevant to tumor invasion and metastasis. Researchers can utilize PRSS21 antibodies to investigate expression patterns across different cancer types and correlate them with clinical outcomes.

Immunohistochemical analysis of tumor tissue microarrays using well-validated PRSS21 antibodies could reveal whether expression levels correlate with tumor grade, stage, or patient prognosis. For such studies, monoclonal antibodies with high specificity, such as clone 2E10 which targets amino acids 121-221 , might offer advantages in terms of reproducibility and reduced background.

Functional studies exploring PRSS21's role in tumor cell behavior could combine antibody-based detection methods with gene silencing approaches. For instance, researchers could use PRSS21 antibodies to confirm protein knockdown after siRNA treatment, as has been done in studies of endothelial cells . Such approaches might reveal whether PRSS21 contributes to processes such as tumor angiogenesis, given its established role in regulating VE-cadherin and vascular integrity . The potential connection between PRSS21 and tumor vasculature represents an intriguing direction for future investigation using antibody-based approaches.